What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy: Ankaflavin, a yellow pigment isolated from Monascus-fermented product, may increase life span, via up-regulation of its target gene BubR1
From research findings to Therapeutic Opportunity:
This study suggests, for the first time, that Ankaflavin may function as a longevity promoter. Ankaflavin, by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (fig. 1).
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How ankaflavin increases the expression of BubR1 and extends mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
Citation: Boominathan, L., Lifespan extension therapy: Ankaflavin, a yellow pigment isolated from Monascus-fermented product, may increase life span, via up-regulation of its target gene BubR1, 22/March/2018, 11.55 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org